Fetal brain-directed AAV gene therapy results in rapid, robust, and persistent transduction of mouse choroid plexus epithelia

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e101-

  Haddad, Marie Reine ^a   Donsante, Anthony ^a   Zerfas, Patricia ^b   Kaler, Stephen G ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

blood cerebrospinal fluid barrier; choroid plexus; in utero gene therapy; rAAV5; rAAV9; survival surgery

Indexed keywords

GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHOROID PLEXUS; CHOROID PLEXUS EPITHELIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GLIA CELL; MOUSE; NERVE CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; SYSTEMATIC REVIEW; TRANSGENE;

EID: 84879984498     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.27     Document Type: Article

References (36)

1. Roybal, JL, Endo, M, Buckley, SM, Herbert, BR, Waddington, SN and Flake, AW (2012). Animal models for prenatal gene therapy: rodent models for prenatal gene therapy. Methods Mol Biol 891: 201-218
2. Currle, DS, Cheng, X, Hsu, CM and Monuki, ES (2005). Direct and indirect roles of CNS dorsal midline cells in choroid plexus epithelia formation. Development 132: 3549-3559 (Pubitemid 41246128)
3. Dziegielewska, KM, Ek, J, Habgood, MD and Saunders, NR (2001). Development of the choroid plexus. Microsc Res Tech 52: 5-20 (Pubitemid 32065024)
4. Wolburg, H and Paulus, W (2010). Choroid plexus: biology and pathology. Acta Neuropathol 119: 75-88
5. Redzic, ZB, Preston, JE, Duncan, JA, Chodobski, A and Szmydynger-Chodobska, J (2005). The choroid plexus-cerebrospinal fluid system: from development to aging. Curr Top Dev Biol 71: 1-52 (Pubitemid 43588887)
6. Donsante, A, Yi, L, Zerfas, PM, Brinster, LR, Sullivan, P, Goldstein, DS et al. (2011). ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model. Mol Ther 19: 2114-2123
7. Kaler, SG (2011). ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol 7: 15-29
8. Watson, DJ, Passini, MA and Wolfe, JH (2005). Transduction of the choroid plexus and ependyma in neonatal mouse brain by vesicular stomatitis virus glycoprotein-pseudotyped lentivirus and adeno-associated virus type 5 vectors. Hum Gene Ther 16: 49-56 (Pubitemid 40250331)
9. Passini, MA, Watson, DJ, Vite, CH, Landsburg, DJ, Feigenbaum, AL and Wolfe, JH (2003). Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol 77: 7034-7040 (Pubitemid 36666896)
10. Dodge, JC, Treleaven, CM, Fidler, JA, Hester, M, Haidet, A, Handy, C et al. (2010). AAV4- mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther 18: 2075-2084
11. Broekman, ML, Comer, LA, Hyman, BT and Sena-Esteves, M (2006). Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138: 501-510 (Pubitemid 43255560)
12. Rafi, MA, Rao, HZ, Luzi, P, Curtis, MT and Wenger, DA (2012). Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther 20: 2031-2042
13. Liu, G, Martins, I, Wemmie, JA, Chiorini, JA and Davidson, BL (2005). Functional correction of CNS phenotypes in a lysosomal storage disease model using adenoassociated virus type 4 vectors. J Neurosci 25: 9321-9327 (Pubitemid 41464744)
14. Karolewski, BA and Wolfe, JH (2006). Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol Ther 14: 14-24 (Pubitemid 43899484)
15. Cachón-Gonzalez, MB, Wang, SZ, McNair, R, Bradley, J, Lunn, D, Ziegler, R et al. (2012). Gene transfer corrects acute GM2 gangliosidosis- potential therapeutic contribution of perivascular enzyme flow. Mol Ther 20: 1489-1500
16. Donsante, A, Haddad, MR and Kaler, SG (2012). Directed evolution to create choroid plexus-permissive AAV capsid variants. Mol Ther 20 (suppl. 1): S229.
17. Wolfe, JH (2011) Viral vector gene delivery to the brain to treat the disseminated lesions of neurogenetic diseases: focus on lysosomal storage diseases. In: Glorioso, J (ed.). Gene Vector Design and Application to Treat Nervous System Disorders. Society for Neuroscience: Washington, DC. pp. 25-32
18. Escolar, ML, Poe, MD, Provenzale, JM, Richards, KC, Allison, J, Wood, S et al. (2005). Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 352: 2069-2081 (Pubitemid 40664308)
19. Fratantoni, JC, Hall, CW and Neufeld, EF (1968). Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162: 570-572
20. Duffner, PK, Caviness, VS Jr, Erbe, RW, Patterson, MC, Schultz, KR, Wenger, DA et al. (2009). The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 11: 450-454
21. Hemsley, KM and Hopwood, JJ (2009). Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Int J Clin Pharmacol Ther 47 (suppl. 1): S118-S123
22. Dierenfeld, AD, McEntee, MF, Vogler, CA, Vite, CH, Chen, AH, Passage, M et al. (2010). Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2: 60ra89.
23. Hemsley, KM, King, B and Hopwood, JJ (2007). Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol Genet Metab 90: 313-328 (Pubitemid 46241904)
24. Crawley, AC, Marshall, N, Beard, H, Hassiotis, S, Walsh, V, King, B et al. (2011). Enzyme replacement reduces neuropathology in MPS IIIA dogs. Neurobiol Dis 43: 422-434
25. Lee, WC, Tsoi, YK, Troendle, FJ, DeLucia, MW, Ahmed, Z, Dicky, CA et al. (2007). Singledose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J 21: 2520-2527 (Pubitemid 47230681)
26. Chang, M, Cooper, JD, Sleat, DE, Cheng, SH, Dodge, JC, Passini, MA et al. (2008). Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 16: 649-656 (Pubitemid 351426165)
27. Rennels, ML, Gregory, TF, Blaumanis, OR, Fujimoto, K and Grady, PA (1985). Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 326: 47-63 (Pubitemid 15160009)
28. Rahim, AA, Wong, AM, Hoefer, K, Buckley, SM, Mattar, CN, Cheng, SH et al. (2011). Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J 25: 3505-3518
29. Rahim, AA, Wong, AM, Ahmadi, S, Hoefer, K, Buckley, SM, Hughes, DA et al. (2012). In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression. Gene Ther 19: 936-946
30. McDonald, TF and Green, K (1988). Cell turnover in ciliary epithelium compared to other slow renewing epithelia in the adult mouse. Curr Eye Res 7: 247-252 (Pubitemid 18087596)
31. Liddelow, SA, Dziegielewska, KM, Vandeberg, JL and Saunders, NR (2010). Development of the lateral ventricular choroid plexus in a marsupial, Monodelphis domestica. Cerebrospinal Fluid Res 7: 16.
32. Shen, S, Bryant, KD, Sun, J, Brown, SM, Troupes, A, Pulicherla, N et al. (2012). Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J Virol 86: 10408-10417
33. Flotte, TR, Conlon, TJ, Poirier, A, Campbell-Thompson, M and Byrne, BJ (2007). Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites. Hum Gene Ther 18: 245-256 (Pubitemid 46626463)
34. Salegio, EA, Samaranch, L, Jenkins, RW, Clarke, CJ, Lamarre, C, Beyer, J et al. (2012). Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther 23: 891-902
35. Mattar, CN, Waddington, SN, Biswas, A, Johana, N, Ng, XW, Fisk, AS et al. (2013). Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther 20: 69-83
36. Dawson-Saunders, B and Trapp, RG (1994). Basic and Clinical Biostatistics, 2nd edn. Appleton & Lange: Norwalk, CT. pp. 344.